RADX

BEARISH

$4.58 Live

Radiopharm Theranostics Limited · NASDAQ

Target $18.05 (+294.1%)

$3.62 52W Range $16.25

RADX Radiopharm Theranostics Limited - Fundamental Analysis

BEARISH

Console Chart News

RADX Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$4.58

Analyst Target

$18.05

+294.1% Upside

52W High

$16.25

52W Low

$3.62

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$36.1M

P/E

N/A

ROE

-92.1%

Profit margin

-286.2%

Debt/Equity

N/A

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

RADX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of valuation benchmarks like the Graham Number due to negative earnings. While the company shows impressive YoY revenue growth of 154.50% and maintains strong short-term liquidity (Current Ratio 3.01), these are overshadowed by a catastrophic negative gross margin of -136.51%. The stock is in a severe technical downtrend, having collapsed from a 52-week high of $16.25 to $4.58, suggesting a significant loss of investor confidence despite optimistic analyst price targets.

Key Strengths

Exceptional YoY revenue growth of 154.50%

Strong liquidity position with a Current Ratio of 3.01

Low Price-to-Sales ratio (2.22) relative to biotech peers

Significant gap between current price and analyst target price ($18.05)

Reasonable Price-to-Book ratio of 1.43

Key Risks

Negative gross margins indicate the cost of producing goods exceeds revenue

Severe operating losses with an operating margin of -423.75%

Extreme technical weakness (Technical Trend score 0/100)

Poor insider sentiment (40/100) suggesting lack of internal confidence

High volatility and significant price depreciation from 52-week highs

AI Fair Value Estimate

Based on comprehensive analysis

$6.2

+35.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative / High Risk

Key drivers: Negative Gross Margins, Technical Collapse, High Revenue Growth, Strong Liquidity

Confidence

90%

Value

30/100

Valuation is impossible via traditional earnings metrics; trading on speculative growth.

Positives

Low P/S ratio

Watchpoints

Negative P/E
No Graham Number available due to losses

Future

70/100

Growth is strong, but the business model is not yet monetizing efficiently.

Positives

154.5% Revenue Growth

Watchpoints

Unsustainable burn rate

Past

20/100

Historical price action is overwhelmingly bearish over the medium term.

Positives

1Y change is slightly positive (+6.5%)

Watchpoints

6M change is -35.6%
Massive drop from 52-week high

Health

50/100

Liquidity is the only healthy metric; operational health is poor.

Positives

Current Ratio 3.01
Piotroski F-Score 4/9 (Stable)

Watchpoints

Severe negative ROE (-92.10%)

Dividend

0/100

Typical for early-stage biotech.

Positives

No standout positives identified.

Watchpoints

No dividend paid

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$4.58

Analyst Target

$18.05

Upside/Downside

+294.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RADX and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
RADX Radiopharm Theranostics Limited Primary	-74.1%	-74.1%	+6.5%	-35.6%	-2.5%	-1.7%
PLUR Pluri Inc. Peer	-89.3%	-51.8%	-3.0%	-19.3%	+8.7%	+3.5%
NMTC NeuroOne Medical Technologies Corporation Peer	-88.5%	-57.8%	+32.2%	-19.5%	+1.4%	-12.1%
ATRA Atara Biotherapeutics, Inc. Peer	-98.9%	-95.6%	-24.7%	-54.9%	-70.3%	+15.0%
BDMD Baird Medical Investment Holdings Limited Peer	-89.3%	-90.0%	-87.4%	-49.5%	-26.9%	-10.4%

RAD

Radiopharm Theranostics Limited

Primary

-74.1%

+6.5%

-35.6%

-2.5%

-1.7%

PLU

Pluri Inc.

Peer

-89.3%

-51.8%

-3.0%

-19.3%

+8.7%

+3.5%

NMT

NeuroOne Medical Technologies Corporation

Peer

-88.5%

-57.8%

+32.2%

-19.5%

+1.4%

-12.1%

ATR

Atara Biotherapeutics, Inc.

Peer

-98.9%

-95.6%

-24.7%

-54.9%

-70.3%

+15.0%

BDM

Baird Medical Investment Holdings Limited

Peer

-89.3%

-90.0%

-87.4%

-49.5%

-26.9%

-10.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-1.75

N/A

1.43

2.22

994.95

-413.38

$36.1M

Profitability

Profit margins and return metrics

Profit Margin -286.16%

Operating Margin -423.75%

Gross Margin -136.51%

ROE -92.1%

ROA -28.33%

Growth

Revenue and earnings growth rates

Revenue Growth +154.5%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

N/A

Current Ratio

3.01

Strong

Quick Ratio

3.0

Excellent

Cash/Share

$0.01

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2024

Total Assets

$0.1B

Liabilities

$0.0B

Equity

$0.1B

Debt/Equity

0.76x

Healthcare Sector Comparison

Comparing RADX against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)

Return on Equity (ROE)

-92.1%

This Stock

-100.15%

Sector Avg

-8.0% (Below Avg)

Profit Margin

-286.16%

This Stock

-13.63%

Sector Avg

+1999.7% (Superior)

Revenue Growth

154.5%

This Stock

121.05%

Sector Avg

+27.6% (Fast Growth)

Current Ratio

3.01

This Stock

4.55

Sector Avg

-33.8% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
RADX Radiopharm Theranostics Limited	BEARISH	$36.1M	-	-92.1%	-286.2%	$4.58
PLUR Pluri Inc.	BEARISH	$35.28M	-	-%	-%	$3.51	Compare
NMTC NeuroOne Medical...	BEARISH	$37.01M	-	-146.3%	-58.3%	$0.73	Compare
ATRA Atara Biotherapeutics, Inc.	BEARISH	$37.64M	1.83	-%	15.4%	$5.22	Compare
BDMD Baird Medical Investment...	BEARISH	$37.83M	-	-8.0%	-10.0%	$1.03	Compare

RADX Radiopharm...

BEARISH

Mkt Cap

$36M

P/E

ROE

-92.1%

Price

$4.58

Compare with RADX

Compare with RADX

Compare with RADX

BDMD Baird Medical...

Compare with RADX

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F

ANNUAL REPORT

2025-09-18

RADX filed its annual report on Form 20-F on September 18, 2025. Due to the limited information provided, specific financial highlights and risk factors are not available for summary.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

5 analysts

B. Riley Securities

2025-12-16

reit

Buy Buy

B. Riley Securities

2025-11-26

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning RADX from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

RADX

RADX Radiopharm Theranostics Limited - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Healthcare Sector Comparison

Similar Companies

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!